Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

ClinicalTrials.gov ID: NCT06661915

Public ClinicalTrials.gov record NCT06661915. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with iadademstat may be more effective than ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative MPNs.

Study identification

NCT ID
NCT06661915
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
78 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 13, 2025
Primary completion
Dec 30, 2027
Completion
Dec 30, 2027
Last update posted
Aug 31, 2026

2025 – 2027

United States locations

U.S. sites
31
U.S. states
13
U.S. cities
30
Facility City State ZIP Site status
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine California 92612 Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California 92868 Recruiting
Stanford Cancer Institute Palo Alto Palo Alto California 94304 Recruiting
University of California Davis Comprehensive Cancer Center Sacramento California 95817 Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables Florida 33146 Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Springs Coral Springs Florida 33065 Recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach Florida 33442 Recruiting
UM Sylvester Comprehensive Cancer Center at Doral Doral Florida 33166 Recruiting
UM Sylvester Comprehensive Cancer Center at Hollywood Hollywood Florida 33021 Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136 Recruiting
UM Sylvester Comprehensive Cancer Center at Kendall Miami Florida 33176 Recruiting
University of Miami Sylvester Comprehensive Cancer Center at Sole Mia North Miami Florida 33181 Recruiting
UM Sylvester Comprehensive Cancer Center at Plantation Plantation Florida 33324 Recruiting
Moffitt Cancer Center Tampa Florida 33612 Recruiting
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637 Recruiting
UC Comprehensive Cancer Center at Silver Cross New Lenox Illinois 60451 Recruiting
University of Chicago Medicine-Orland Park Orland Park Illinois 60462 Recruiting
UChicago Medicine Northwest Indiana Crown Point Indiana 46307 Recruiting
University of Kansas Clinical Research Center Fairway Kansas 66205 Recruiting
University of Kansas Cancer Center Kansas City Kansas 66160 Recruiting
University of Kansas Hospital-Indian Creek Campus Overland Park Kansas 66211 Recruiting
University of Kansas Hospital-Westwood Cancer Center Westwood Kansas 66205 Recruiting
NYP/Weill Cornell Medical Center New York New York 10065 Recruiting
Carolinas Medical Center/Levine Cancer Institute Charlotte North Carolina 28203 Recruiting
Atrium Health Cabarrus/LCI-Concord Concord North Carolina 28025 Recruiting
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 Recruiting
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 Recruiting
Oregon Health and Science University Portland Oregon 97239 Recruiting
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232 Recruiting
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 Recruiting
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06661915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 31, 2026 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06661915 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →